ストックスクリーナーアプリを入手
10.03
4.39%
-0.46
プレマーケット:
10.12
0.09
+0.90%
Zevra Therapeutics Inc (ZVRA) 最新ニュース
Lightning eMotors Inc. (ZEV) - Minichart
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
ZVRA: AI-driven patient identification and global expansion fuel growth and pipeline acceleration - TradingView
ZVRA News | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Understanding Momentum Shifts in (ZVRA) - Stock Traders Daily
Zevra Therapeutics CEO to present company updates at H.C. Wainwright BioConnect Investor Conference - Traders Union
Zevra Therapeutics details arimoclomol and miglustat study findings for rare disease event - Traders Union
Did One-Off-Boosted Q1 Profits Just Shift Zevra Therapeutics' (ZVRA) Investment Narrative? - Sahm
A Look At Zevra Therapeutics (ZVRA) Valuation After Strong Earnings And SDX Portfolio Sale - Sahm
EDGAR Filing Documents for 0001434647-26-000021 - SEC.gov
Zevra Therapeutics (ZVRA) legal chief sells 1,794 shares under 10b5-1 plan - Stock Titan
Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear - Yahoo Finance
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference - The Manila Times
TradingKey - TradingKey
[144] ZEVRA THERAPEUTICS, INC. SEC Filing - Stock Titan
HC Wainwright Analysts Increase Earnings Estimates for ZVRA - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Earnings Call Highlights Growth Pivot - TipRanks
Number of shareholders of Zevra Therapeutics, Inc. – NASDAQ:ZVRA - TradingView
Zevra Therapeutics (ZVRA) Is Up 8.2% After Debt-Free Turnaround And Rare Disease Refocus – What’s Changed - Sahm
Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
ZVRA Maintained by Guggenheim -- Price Target Raised to $25.00 - GuruFocus
Zevra Therapeutics price target raised to $25 from $23 at Guggenheim - TipRanks
Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Investors Eye 107% Upside Potential - DirectorsTalk Interviews
Has Zevra Therapeutics (ZVRA) Finally Turned the Corner - Kavout
Zevra Therapeutics Q1 2026 Earnings: Revenue Surges 78% to $36.2M - IndexBox
Avoiding Lag: Real-Time Signals in (ZVRA) Movement - Stock Traders Daily
Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge? - Yahoo Finance
CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Zevra Therapeutics, Inc. Q1 2026 Financial Results and Forward-Looking Statements – Quarterly Report Highlights - Minichart
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2026 Earnings Call Transcript - Insider Monkey
Zevra Therapeutics: Buy Rating Reiterated as MIPLYFFA Execution, Debt-Free Balance Sheet Support Upside with Price Target Maintained at $26 - TipRanks
Zevra Therapeutics Q1 Earnings Call Highlights - MarketBeat
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
MSN Money - MSN
Zevra Reports First Quarter 2026 Financial Results and Corporate Update - The Manila Times
Zevra outlines celiprolol interim analysis trigger at 28 events while expanding MIPLYFFA access - MSN
Earnings call transcript: Zevra Therapeutics Q1 2026 beats expectations with strong revenue growth By Investing.com - Investing.com Australia
Zevra Therapeutics (ZVRA) Q1 earnings and revenues surpass estimates - MSN
Zevra Therapeutics reports Q1 EPS 60c, consensus 8c - TipRanks
Zevra Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Zevra (ZVRA) Q1 2026 Earnings Call Transcript - AOL.com
ZVRA: Q1 2026 delivered 78% revenue growth, debt-free status, and expanded rare disease reach - TradingView
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Earnings call transcript: Zevra Therapeutics Q1 2026 beats expectations with strong revenue growth - Investing.com Nigeria
Zevra Therapeutics (ZVRA) turns profit, clears $63M debt with SDX sale - Stock Titan
Zevra Therapeutics (NASDAQ:ZVRA) Shares Surge After Blowout Q1 Earnings Beat - ChartMill
Zevra Therapeutics Inc. (ZVRA) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Zevra Therapeutics: Q1 Earnings Snapshot - Barchart.com
Q1 2026 Zevra Therapeutics Inc Earnings Call Transcript - GuruFocus
Debt-free after asset sale, Zevra ends quarter with $236.8M cash - Stock Titan
Zevra (NASDAQ: ZVRA) swings to Q1 profit and repays term loan - Stock Titan
FMR LLC reports 3.21M-share stake in Zevra Therapeutics (NASDAQ: ZVRA) - Stock Titan
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):